As we await approval, we are focusing on preparing the Company for the upcoming launch. We have as part of this effort started the process of signing agreements with European distributors and preparing an aggressive release plan for the United States. Moreover, we are scaling up production and contracting third-party providers to meet the market demand that we have identified. This relates in particular to the launch of the product for home use.
Our hope is to be able to start selling within a week’s or a few weeks’ time. The CE marking process and the authorization process with the FDA are well underway, and as soon as Aegirbio has received sufficient data from the clinical studies, the Company will start marketing the product.
“Very annoying to fumble near the goal line and having to postpone the launch of sales; we have a product that both we and our distributors have a lot of confidence in, but we have to reach the right number of patients before we can finalize the CE marking and the FDA process. Nevertheless, we are very happy to see that demand is growing day by day, and we believe that we will be able to sign agreements with several strong distributors connected to the health care system, pharmacies and retail,” says CEO Martin Linde.